Life Sciences

  • May 14, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Members of Congress approved language in a funding bill that would block the rescheduling of marijuana, Colorado lawmakers gave final approval to a bill to fund research into the psychedelic ibogaine and authorize the establishment of licensed treatment centers, and Rhode Island lawmakers introduced legislation to eliminate geographic criteria from the state's cannabis social equity program.

  • May 14, 2026

    NC Republicans Want Fetal Personhood Question On '26 Ballot

    Two Republicans in the North Carolina House who have a history of advancing so-called fetal personhood bills have made another attempt to put a constitutional amendment to voters in November to decide if life begins at fertilization.

  • May 14, 2026

    Takeda To Pay $13.6M Over Antidepressant Drug Kickbacks

    Takeda Pharmaceuticals will pay $13.6 million to end allegations that it caused false Medicaid claims by providing kickbacks to healthcare providers to push prescriptions of its antidepressant drug Trintellix, the U.S. Department of Justice announced Thursday.

  • May 14, 2026

    Human Reproduction Proves Talc Can Reach Ovaries, Jury Told

    A medical oncologist on Thursday told a Los Angeles bellwether jury considering claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that the female reproductive system is an "open" system where talc can migrate to the ovaries, and that "we wouldn't exist" if that was not the case.

  • May 14, 2026

    Squires Walks Back 5 More IPR Grants Over Inconsistent Args

    U.S. Patent and Trademark Office Director John Squires has reversed earlier decisions granting five petitions for patent review, citing what he called the challengers' inconsistent positions in parallel proceedings and explaining that four petitions he denied in previous bulk orders were also rejected for the same reasons. 

  • May 14, 2026

    House Passes Bill To Narrow Biofuel Blending Exemption

    The U.S. House of Representatives has passed a bill that would lift summertime restrictions on the sale of higher-ethanol fuel and tighten requirements for a biofuel blending exemption for small refineries.

  • May 14, 2026

    Med Device Co.'s CEO Touted Growth, Netted $39M, Suit Says

    Medical device maker Integer Holdings Corp.'s former CEO overstated growth prospects of a manufacturing program for the company's electrophysiology business, inflating the firm's stock price and allowing him to reap a nearly $39 million "windfall net profit," according to an investor's derivative lawsuit in Texas federal court.

  • May 14, 2026

    Albertsons Not Covered In Opioid Litigation, Del. Judge Says

    Albertsons isn't entitled to defense or indemnity for more than 100 suits accusing the pharmacy and grocery chain of fueling the opioid epidemic, a Delaware state court ruled, tracking the state high court's rulings in nearly identical disputes involving Rite Aid and CVS.

  • May 14, 2026

    Insider Trading Case Shows BigLaw Associate Vetting Gaps

    A BigLaw attorney who was able to move through three major firms while allegedly orchestrating a massive insider trading scheme may have been aided by relatively loose hiring practices for associates that firms may consider strengthening moving forward, recruiting experts told Law360.

  • May 14, 2026

    Fortive, Subsidiary Seek Early Win In Wrongful Firing Suit

    Technology company Fortive and a medical equipment subsidiary asked a Colorado federal judge for an early win in a former regional sales director's lawsuit alleging she was fired for raising concerns about compliance with anti-kickback rules, contending the subsidiary terminated her due to a restructuring and that Fortive wasn't her employer.

  • May 14, 2026

    High Court Maintains Abortion Pill Access Amid Circuit Appeal

    The U.S. Supreme Court on Thursday extended a stay preserving telehealth access to the abortion medication mifepristone while the Fifth Circuit weighs a challenge to the mail-order distribution of the pill.

  • May 14, 2026

    Takeda Cashed In From Delay Of Generic IBS Drug, Jury Told

    Drug buyers urged a Massachusetts federal jury on Thursday to find that Takeda Pharmaceuticals conspired with another drugmaker to keep a generic version of anticonstipation drug Amitiza off the market in order to boost its own profits. 

  • May 14, 2026

    BeiGene Must Face AbbVie's Chemical Trade Secret Claims

    An Illinois federal judge has denied oncological research company BeiGene's request to escape claims from AbbVie Inc. that it poached a retired scientist to obtain trade secrets related to a certain chemical compound, saying BeiGene failed to back up its arguments.

  • May 14, 2026

    Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout

    A former equity holder of Clario Holdings Inc., a clinical-trial technology company, has sued in the Delaware Chancery Court, seeking records she says she needs to understand how her payout was calculated after Thermo Fisher Scientific Inc.'s $8.875 billion cash acquisition of Clario.

  • May 14, 2026

    Ga. Panel Quiet On Fate Of $20M Bard Cancer Verdict

    A Georgia appellate panel gave few indications Thursday of whether it would order a new trial in a former C.R. Bard worker's lawsuit alleging that exposure to ethylene oxide caused his cancer, weighing whether a mistrial on punitive damages necessitates scrapping a $20 million compensatory damages verdict.

  • May 14, 2026

    Time For Trial, Judge Says, Nixing DQ Appeal In Generics MDL

    A Pennsylvania federal judge has refused to let generic-drug makers seek Third Circuit intervention in their bid to disqualify the lead counsel for insurers Humana and Molina, concluding the fight would only further delay the long-running case ahead of its first trial in the price-fixing multidistrict litigation.

  • May 13, 2026

    Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug

    The Federal Circuit on Wednesday upheld a lower court's rejection of Actelion Pharmaceuticals' patent case against Viatris Inc. over its planned generic version of Actelion's hypertension drug, finding no issues with the court's approach to pH measurement in the patent.

  • May 13, 2026

    'Powerful' Risk For Women Using Talc, UC Prof Tells Jury

    An epidemiology professor at the University of California, San Francisco testified Wednesday in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused deadly ovarian cancer in three women, saying there are multiple studies concluding the product increases the risk of the disease, including one finding a "very powerful" risk.

  • May 13, 2026

    3 NJ Employers Accused Of Pregnancy Discrimination

    A New Jersey hospital system, a laboratory company and a cleaning business must answer to allegations that they engaged in pregnancy discrimination in the workplace, state enforcers said this week.

  • May 13, 2026

    Walgreens Investors' Opioid Suit Is Time-Barred, Judge Says

    Pharmacy giant Walgreens no longer faces a proposed class action alleging it hurt investors when it disclosed opioid-related litigation losses after a Chicago federal judge found the claims were time-barred.

  • May 13, 2026

    Pa. Jury Finds Dispensary Subjected Fired Manager To Bias

    A Pennsylvania federal jury has awarded $203,500 to a dispensary employee who claimed Restore Integrative Wellness Center discriminated against him by terminating his employment after he went on leave to recover from injuries sustained in a car accident.

  • May 13, 2026

    Bayer, Buyers Get Final OK Of $4.85M Benzene Settlement

    A New Jersey federal judge on Wednesday gave final approval to a $4.85 million settlement to end claims against Bayer Healthcare LLC and others alleging that antifungal products were contaminated with benzene.

  • May 13, 2026

    Becton Hernia Mesh Antitrust Case Survives Dismissal

    A Pennsylvania federal court has refused to toss an antitrust case from Tela Bio Inc. accusing Becton Dickinson & Co. of abusing its dominant position in the hernia mesh market to block competing products.

  • May 13, 2026

    Conn. Doctor Asked To Pay $880K In IVF Fraud Dispute

    Two people who accused a reproductive endocrinologist of using his own sperm to impregnate their mothers have proposed that the doctor settle their suit against him for a total of $880,000, according to separate offers filed in Connecticut state court.

  • May 13, 2026

    Crowell & Moring Opens Minneapolis Office With 8 Lawyers

    Crowell & Moring LLP announced Wednesday that it is deepening its commitment to Minnesota by opening a new office in Minneapolis with a team of eight attorneys and said it's expecting more growth in the near future.

Expert Analysis

  • Accelerated Psychedelic Therapy Pathways Require Caution

    Author Photo

    President Donald Trump's new executive order aiming to accelerate the approval of psychedelic drugs for the treatment of mental health disorders will likely bolster investigational psychedelic therapies, but parties within the psychedelic product supply chain will still need to prepare for potentially burdensome compliance requirements, say attorneys at Morgan Lewis.

  • Heppner Ruling Left AI Privilege Risk For Lawyers Unresolved

    Author Photo

    While a New York federal judge’s recent ruling in U.S. v. Heppner resolved a privilege question surrounding client-side artificial intelligence use, it did not address how to mitigate the risks that can arise when confidential information enters the operative context of an AI system used by an attorney, says Jianfei Chen at Quarles & Brady​​​​​​​.

  • How 10 Years Of Case Law Have Shaped The DTSA

    Author Photo

    As the Defend Trade Secrets Act reaches its 10th anniversary, attorneys at Ropes & Gray examine recent DTSA case law and highlight key takeaways regarding pleading requirements, damages and risk factors.

  • The Ethics And Practicalities Of Representing AI Agents

    Author Photo

    With autonomous artificial intelligence agents now able to take action without explicit instructions from — or the awareness of — their human owners, the bar must confront whether existing frameworks like informed consent and client privilege will be sufficient on the day an AI agent calls seeking counsel, say attorneys at Morrison Cohen.

  • Series

    Speed Jigsaw Puzzling Makes Me A Better Lawyer

    Author Photo

    My passion for speed puzzling — I can complete a 500-piece jigsaw puzzle in under 50 minutes — has sharpened my legal skills in more ways than one, with both disciplines requiring patience, precision and the ability to keep the bigger picture in mind while working through the details, says Tazia Statucki at Proskauer.

  • Opinion

    Congress Should Ax Privacy Bill For Not Shielding Consumers

    Author Photo

    The SECURE Data Act should be rejected because, despite Congress' claims, it would not meaningfully rein in data practices, but instead would weaken enforcement, eliminate stronger protections and prioritize data extraction over consumer protection and accountability, say attorneys at DiCello Levitt.

  • Suit's Dismissal Would Not Settle Gold Card Visa's Legality

    Author Photo

    The government’s recent assertion that the plaintiffs in American Association of University Professors v. Department of Homeland Security lack standing to challenge the Trump administration’s pay-to-play immigration program does not address whether an agency can deem a million-dollar gift evidence of eligibility for immigration benefits carefully defined by Congress, says Jun Li at Reid & Wise.

  • 2 AI Snafus Show Why Attys Can't Outsource Judgment

    Author Photo

    The recent incident involving Sullivan & Cromwell where citations in a filed motion were fabricated by artificial intelligence, as well as a punitive ruling from the Sixth Circuit in U.S. v. Farris, demonstrate that the obligation to supervise AI has belonged and always will belong to lawyers, says John Powell at the Kentucky School Boards Association.

  • Opinion

    Congress Must Repair USPTO's Inter Partes Review Process

    Author Photo

    To challenge recent changes to the inter partes review process issued by the U.S. Patent and Trademark Office, Congress must establish clear statutory guardrails, transparency and meaningful judicial review so that questionable patents receive proper scrutiny, say Sean Tu at the University of Alabama, Arti Rai at Duke University and Aaron Kesselheim at Harvard.

  • Previewing FDA Preapproval Access In Psychedelics EO

    Author Photo

    The second of two pathways for psychedelic drug access outlined in President Donald Trump's recent executive order constitutes an unprecedented expansion of the Right to Try Act, which could fundamentally alter the psychedelic access landscape while presenting significant regulatory, operational and legal challenges, say attorneys at Husch Blackwell.

  • NY's Growing Enviro Reg Framework Will Transform Projects

    Author Photo

    Three closely connected environmental rulemakings in New York state — concerning greenhouse gas reporting, remediation standards and amendments to the State Environmental Quality Review Act — have reached critical stages, and taken together, they will have major impacts on business operations, construction project timelines and transactional risk, say attorneys at Holland & Knight.

  • How 'Spillover' Effects Can Skew AI Securities Class Actions

    Author Photo

    Event study evidence is often central in securities litigation at class certification and beyond, but in an environment where earnings forecasts and statements can have spillover market implications, particularly when concerning artificial intelligence, the task of parsing out the price impact of news requires careful consideration, say Erik Johannesson, Olivia Wurgaft and Nguyet Nguyen at Brattle Group.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.